Adma Biologics Inc. (ADMA) Trading Up 2.6%
Adma Biologics Inc. (NASDAQ:ADMA) was up 2.6% during trading on Friday . The company traded as high as $5.67 and last traded at $5.61, with a volume of 61,749 shares. The stock had previously closed at $5.47.
Several research firms have recently issued reports on ADMA. Maxim Group reduced their price objective on shares of Adma Biologics from $24.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, July 25th. Raymond James Financial Inc. cut shares of Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research report on Monday, August 1st.
The stock’s 50 day moving average is $6.51 and its 200-day moving average is $6.38. The company’s market cap is $72.29 million.
Adma Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.11. On average, equities analysts expect that Adma Biologics Inc. will post ($1.83) EPS for the current year.
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.